Coronavirus Pandemic: What Nuclear Medicine Departments Should Know

The Impact of the Coronavirus Disease 2019 Pandemic on the Clinical Environment

The Nuclear Medicine Technology Certification Board performed an impact survey on the coronavirus disease 2019 pandemic to better assess the current state of nuclear medicine practice within the United States, as well as the perceptions and experiences of technologists working during the pandemic. Methods: A web-based automation platform was used to create, collect, and analyze the survey data. Results: The survey revealed many department protocol variations during the pandemic, a decrease in patient volume, and several other concerns and issues. Experiences regarding staffing and wage changes were varied. Conclusion: This research showed significant inconsistencies in practice and stresses to nuclear medicine technology during the pandemic, as well as concerns for the workforce pipeline. NMTCB decided to delay the JTA process and conduct additional research regarding the workforce.

Updated clinical management guidance during the COVID-19 pandemic: thyroid nodules and cancer

Healthcare settings, including nuclear medicine (NM) departments, promptly adjusted their standard operating procedures to cope with the unprecedented crisis caused by coronavirus disease 19 (COVID-19) pandemic. Nuclear thyroidology has adopted changes and predicated on a careful risk-benefit analysis, in order to prevent a potential spread of the virus while being at the same time effective, safe and preserving their quality of essential services. Since most thyroid nodules (TNs) are benign, and malignant neoplasms are characterized by an indolent natural history, it is generally safe to delay diagnostic and therapeutic procedures. In this respect, the main adjustments that nuclear thyroidology has adopted are summarized into the following: general workplace adjustments including remote work for NM staff; postponing appointments for consultation, diagnostic and therapeutic purposes and rescheduling based on individualized risk stratification; telemedicine; preparation for possible issues on radiopharmaceuticals synthesis and delivery; preventing measures and protocols to minimize or avoid potential COVID-19 infection of patients and medical staff. This document should be considered as updated guidance on how clinical management of TNs and thyroid cancer has been altered, remodeled and adapted to the new circumstances in the COVID-19 era, based on the rapidly growing volume of scientific information regarding the new coronavirus.

Imaging of Hematological Patients in the Era of COVID-19

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulted in changes in management and imaging routines for patients with hematological malignancies. Treating physicians had to familiarize themselves with a new disease, with distinct imaging manifestations, sometimes overlapping with other infections prevalent in this patient population. In some aspects, infected hematological patients might exhibit a different disease course, and routine imaging in asymptomatic hematological patients may result in unexpected COVID-19 findings, implying covert infection, that should be further explored. Furthermore, some complications of hematological diseases and treatments may present with findings similar to COVID-19 manifestations, and treating physicians must consider both possibilities in the differential diagnosis. In this review, we aimed to present the influence the COVID-19 pandemic had on hematological malignancy imaging.

Nuclear medicine practices during the COVID-19 pandemic—review of some recently published protocols

Background

With the global surge in COVID-19 pandemic, it has become inevitable for everyone, inclusive of nuclear medicine personnel, to play their role in combating and containing its transmission. During fall 2019, China encountered a novel coronavirus in Wuhan city which was later on termed as COVID-19. The pneumonia caused by COVID-19 is characterized by dry cough, fever, fatigue, and shortness of breathing (dyspnea). Until now, this virus has spread worldwide and continues to cause exponential causalities.

Main body

This global catastrophic scenario calls for stringent measures to control COVID-19 infection. Thus herein, the respective authors have endeavored to review precautionary measures for nuclear medicine department, encompassing its personnel as well as the patients so that intradepartmental transmission can be prevented. This requires development and execution of a robust and dynamic plan elaborating the healthcare guidelines. Hence, our review paper covers the arena of nuclear medicine services in particular.

Conclusion

Nuclear medicine can play its role in mitigating COVID-19 transmission to personnel and patients if provided with ample PPEs and guidelines are strictly followed. With implementing SOPs (standard operating procedures) based on these guidelines, nuclear medicine facilities will be better prepared for impromptu actions in case of any future outbreak while retaining the smooth flow of obligatory healthcare services.

Post-COVID-19 New Normal for Molecular Imaging Departments: A United Kingdom Perspective

Coronavirus disease 2019 has changed the way the world is navigated and has had a massive impact on health care. Depending on where you are in the world, the guidance on dealing with potential infected patients is varied. With the high risk of a second wave, it is important to learn from initial responses to plan for the future. With proper preparation, it is possible to minimize exposure and risk of contamination to individuals visiting molecular imaging departments. Such precautions will help departments operate at full capacity. From the widespread nature of this pandemic, a global perspective can be useful; what follows is the United Kingdom's perspective.